Calliditas Therapeutics AB planned the commercialization of its first rare disease product, Nefecon (budesonide), in the US, and expanded its development pipeline through its first major product candidate acquisition , as its coped with last year’s COVID-19-related travel restrictions and changing business processes.
Looking back, CEO Renee Aguiar-Lucander is relieved the Stockholm, Sweden-based company began executing its commercialization strategy relatively early. “We started...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
